Genetic and Molecular Markers of Urothelial Premalignancy and Malignancy

REFERENCES

• Reuter VE, Melamed MR. The lower urinary tract. In: Sternberg SS, ed. Diagnostic surgical pathology. New York: Raven Press, 1989: 1355.
   Google Scholar
• Zhang Z-F, Steineck G. Epidemiology and etiology of bladder cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P, eds. Principles and practice of genitourinary oncology. Philadelphia, PA: J.B. Lippincott Company, 1996.
   Google Scholar
• Mostofi FK, Sesterhenn IA. Pathology of epithelial tumors and carcinoma in situ of bladder. Prog Clin Biol Res 1984; 62: 55–74.
   Google Scholar
• Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993; 324: 469–71.
   Google Scholar
• Spruck CH, Ohneseit PE, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784–8.
   Google Scholar
• Johansson SL, Cohen SM. Pathology of bladder cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P, eds. Principles and practice of genitourinary oncology. Philadelphia, PA: J. B. Lippincott Company, 1997: 207–13.
   Google Scholar
• Koss L Diagnostic cytology and its histopathologic bases, 4th edn. Philadelphia, PA: J. B. Lippincott Company, 1992.
   Google Scholar
• Kiemeney LA, Witjes JA, Heijbroek RP, Debruyne FM, Verbeek AL. Dysplasia in normal-looking urothe-lium increases the risk of tumour progression in primary superficial bladder cancer. Eur J Cancer 1994; 30: 1621–5.
   Google Scholar
• Igawa M, Urakami S, Shirakawa H. A mapping of histology and cell proliferation in human bladder cancer: an immunohistochemical study. Hiroshima J Med Sci 1995; 44: 93–7.
   Google Scholar
• Cordon-Cardo C. Mutation of cell cycle regulators: Biological and clinical implications for human neopla-sias. Am J Pathol 1995; 147: 545–60.
   PubMed Web of Science ®Google Scholar
• Cote RJ, Chatterjee SJ. Molecular determinants of outcome in bladder cancer. Cancer J Sci Am 1999; 5: 2–15.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Sheinfeld J, Dalbagni G. Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 1997; 13: 319–27.
   Google Scholar
• Orntoft T, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998; 26: 223–33.
   PubMedGoogle Scholar
• Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999; 91: 1113–24.
   PubMedGoogle Scholar
• Li et al. 1999 (personal communication).
   Google Scholar
• Kastan M, Onkyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304–11.
   Google Scholar
• Sarkis AS, Bajorin DF, Reuter VE, Herr HVV, Netto G, Zhang Z-F, et al. The prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant M-VAC. J Clin Oncol 1995; 13: 1384–90.
   Google Scholar
• Cote RJ, Esrig D, Groshen S. et al. p53 and treatment of bladder cancer. Nature 1997; 385: 123–5.
   Google Scholar
• Whang et al. 1999 (personal communication).
   Google Scholar
• Gibas Z, Prout GR, Connolly JG, Pontes JE, Sandberg AA. Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res 1984; 44: 1257–64.
   Google Scholar
• Atkin NB, Baker MC. Cytogenetic study of ten carcinomas of the bladder: Involvement of chromo-somes 1 and 11. Cancer Genet Cytogenet 1985; 15: 253–68.
   PubMedGoogle Scholar
• Babu VR, Lutz MD, Miles BJ, Farah RN, Weiss L, Van DD. Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histopathology. Cancer Res 1987; 47: 6800–5.
   PubMed Web of Science ®Google Scholar
• Vanni R, Scarpa RM, Nieddu M, Usai E. Cytogenetic investigation on 30 bladder carcinomas. Cancer Genet Cytogenet 1988; 30: 35–42.
   PubMedGoogle Scholar
• Tyrkus M, Powell I, Fakr W. Cytogenetic studies of carcinoma in situ of the bladder: prognostic implica-tions. J Urol 1992; 148: 44–6.
   Google Scholar
• Hopman AHN, Moesker O, Smeets W, Pauwels RPE, Vooijs GP, Ramaekers FCS. Numerical chromosome 1, 7,9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 1991; 51: 644–51.
   PubMed Web of Science ®Google Scholar
• Waldman FM, Carroll PR, Kerschmann R, Cohen MB, Field FG, Maya11 BH. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res 1991; 51: 3807–13.
   Google Scholar
• Sauter G, Deng G, Moch H, et al. Physical deletion of the p53 gene in bladder cancer. Am J Pathol 1994; 144: 756–66.
   PubMed Web of Science ®Google Scholar
• Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818–21.
   PubMed Web of Science ®Google Scholar
• Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Can-cer Res 1997; 57: 2860–4.
   PubMed Web of Science ®Google Scholar
• Wheeless LL, Reeder JE, Han R, et al. Bladder irrigation specimens assayed by fluorescence in situ hybridization to interphase nuclei. Cytometry 1994; 17: 319–26.
   PubMedGoogle Scholar
• Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 bladder carcinoma oncogene. Nature 1982; 300: 149–52.
   PubMed Web of Science ®Google Scholar
• Fujita J, Srivastava SK, Kraus MH. Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proc Nati Acad Sci 1985; 82: 3849–53.
   Google Scholar
• Nagata Y, Abe M, Kobayashi K, et al. Point mutations of c-ras genes in human bladder cancer and kidney cancer. Jpn J Cancer Res 1990; 81: 22–7.
   PubMedGoogle Scholar
• Czemiak B, Deitch D, Simmons H, Elkind P. Herz F, Koss LG. Ha-ras gene codon 12 mutations and DNA ploidy in urinary bladder carcinomas. Br J Cancer 1990; 62: 762–3.
   PubMed Web of Science ®Google Scholar
• Czemiak B, Cohen GL, Elkind P. et al. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Human Pathol 1992; 23: 1199–204.
   Google Scholar
• Ooi A, Herz F, Setsuko I, et al. Ha-ras codon 12 mutation in papillary tumors of the urinary bladder. A retrospective study. Int J Oncol 1994; 4: 85–9.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, Ramchurren N, Rieger K, et al. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Nati Cancer Inst 1995; 87: 129–33.
   PubMed Web of Science ®Google Scholar
• Olderoy G, Daehlin L, Ogreid D. Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res 1998; 18(4A): 2675–8.
   Google Scholar
• Caftan N, Saison-Behmoaras T, Mari B, et al. Screen-ing of human bladder carcinomas for the presence of Ha-ras codon 12 mutation. Oncol Rep 2000; 7: 497–500.
   PubMed Web of Science ®Google Scholar
• Wu et al. 2000 (personal communication).
   Google Scholar
• Neal DE, Marsh C, Bennet MK, Hall RR, Harris AL. Epidermal growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumors. Lancet 1985; 1: 366–8.
   Google Scholar
• Neal DE, Sharpies L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65: 1619–25.
   PubMed Web of Science ®Google Scholar
• Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transi-tional cell carcinomas. Cancer Res 1990; 50: 2530–7.
   PubMed Web of Science ®Google Scholar
• Rao JY, Hemstreet GP, Hurst RE, et al. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Nati Acad Sci USA 1993; 90: 8287–91.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: A multivariate survival analysis. Am J Clin Pathol 1994; 101: 166–76.
   PubMed Web of Science ®Google Scholar
• Wood D, Wartinger DD, Reuter V, Cordon-Cardo C, Fair WR, Chaganti RS. DNA, RNA and immunohis-tochemical characterization of the HER-2/neu onco-gene in transitional cell carcinoma of the bladder. J Urol 1991; 146: 1398–1401.
   Google Scholar
• Sato K, Moriyama M, Mori S, et al. An immunohis-tologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992; 70: 2493–8.
   PubMed Web of Science ®Google Scholar
• Underwood M, Barlett J, Reeves J, Gardiner DS, Scott R, Cooke T. C-erbB-2 gene amplification: A molecular marker in recurrent bladder tumors? Cancer Res 1995; 55: 2422–30.
   PubMed Web of Science ®Google Scholar
• Wagner U, Sauter G, Moch H, et al. Patterns of p53, erB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 1995; 26: 970–8.
   PubMed Web of Science ®Google Scholar
• Oliner JD, Kinzler KW, Metlzer PS, et al. Amplifica-tion of a gene encoding a p53 associated protein in human sarcomas. Nature 1992; 358: 80–3.
   PubMed Web of Science ®Google Scholar
• Pomerantz J, Schrieber-Agus N, Liegoeis N, et al. The Ink4a tumor suppressor gene product, p19/Arf, inter-acts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713–23.
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti G, Olson D, et al. The mdm-2 oncogene product forms a complex with the p-53 protein and inhibits TP53-mediated transactivation. Cell 1992; 69: 1237–45.
   PubMed Web of Science ®Google Scholar
• Lianes P. Orlow I, Zhang ZZ, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994; 86: 1325–30.
   PubMedGoogle Scholar
• Barbareschi M, Girlando S, FeIlin G, Graffer U, Luciani L, Palma PD. Expression of mdm2 and p53 proteins in transitional cell carcinoma. Urol Res 1995; 22: 349–52.
   PubMedGoogle Scholar
• Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971; 68: 820–3.
   PubMed Web of Science ®Google Scholar
• Kiemeney LA, Schoenberg M. Familial transitional cell carcinoma. J Urol 1996; 156: 867–72.
   PubMed Web of Science ®Google Scholar
• Fearon ER, Feinberg AP, Hamilton SH, Vogelstein B. Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 1985; 318: 377–80.
   PubMed Web of Science ®Google Scholar
• Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990; 50: 44–7.
   PubMed Web of Science ®Google Scholar
• Olumi AF, Tsai YC, Nichols PW, et al. Allelic loss of chromosomes 17p distinguishes high grade from low grade transitional cell carcinoma of the bladder. Cancer Res 1990; 50: 7081–3.
   PubMed Web of Science ®Google Scholar
• Presti JC, Reuter VE, Galan T, Fair WR, Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 1991; 51: 5405–9.
   Google Scholar
• Habuchi T, Ogawa O, Kakehi Y, et al. Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 1993; 53: 579–84.
   PubMed Web of Science ®Google Scholar
• Ishikawa J, Xu H-J, Hu S-X, et al. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 1991; 51: 5736–43.
   PubMed Web of Science ®Google Scholar
• Cairns P, Proctor AJ, Knowles MA. Loss of hetero-zygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 1991; 61: 2305–9.
   Google Scholar
• Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product is a prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84: 1251–6.
   Google Scholar
• Logothetis CJ, Xu H-J, Ro JY, et al. Altered retino-blastoma protein expression and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992; 84: 1256–61.
   Google Scholar
• Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, et al. Elevated and absent pRb expression is associated with bladder cancer progression, and has cooperative effects with p53. Cancer Res 1998; 58: 1090–4.
   PubMed Web of Science ®Google Scholar
• Xu HJ, Cairns P, Hu SX, et al. Loss of Rb protein expression in primary bladder cancer correlates with loss of heterozygosity at the Rb locus and tumor progression. Int J Cancer 1993; 53: 781–4.
   PubMed Web of Science ®Google Scholar
• Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252: 706–9.
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Yamada Y, Okajima E, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393–8.
   PubMed Web of Science ®Google Scholar
• Esrig D, Spruck III CH, Nichols PW, et al. P53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389–97.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Dalbagni D, Saez GT, et al. TP53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 1994; 56: 347–53.
   Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53–9.
   Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994; 152: 388–92.
   Google Scholar
• Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259–64.
   PubMed Web of Science ®Google Scholar
• Soini Y, Turpeenniemi-Hujanan T, Kamel D, et al. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease. Br J Cancer 1993; 68: 1029–35.
   PubMed Web of Science ®Google Scholar
• Schmitz-Drager BJ, van Roeyen CR, Grimm MO, et al. p53 accumulation in precursor lesions and early stages of bladder cancer. World J Urol 1994; 12: 79–83.
   Google Scholar
• Stein JP, Ginsberg DA, Grossfeld GD, et al. The effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072–9.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217–21.
   Google Scholar
• Williams BO, Remington L, Albert DM, et al. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 1994; 7: 480–4.
   PubMed Web of Science ®Google Scholar
• Miyao N, Tsai YC, Lerner SP, et al. Role of chromosome 9 in human bladder cancer. Cancer Res 1993; 53: 4066–70.
   PubMed Web of Science ®Google Scholar
• Cairns P, Shaw ME, Knowles MA. Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res 1993; 53: 1230–2.
   Google Scholar
• Orlow I, Lianes P. Lacombe L, Dalbagni G, Reuter VE, Cordon-Cardo C. Chromosome 9 deletions and micro-satellite alterations in human bladder tumors. Cancer Res 1994; 54: 2848–51.
   Google Scholar
• Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–40.
   Google Scholar
• Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704–7.
   Google Scholar
• Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-B-induced cell cycle arrest. Nature 1994; 371: 257–61.
   PubMed Web of Science ®Google Scholar
• Quelle DE, Zindy F, Ashum RA, Sherr CJ. Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993–1000.
   PubMed Web of Science ®Google Scholar
• Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 1998; 18: 6457–73.
   PubMed Web of Science ®Google Scholar
• Orlow I, Lacombe L, Hannon GJ, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995; 87: 1524–9.
   PubMed Web of Science ®Google Scholar
• Gruis NA, Weaver-Feldhaus J, Liu Q, et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995; 146: 1199–206.
   PubMed Web of Science ®Google Scholar
• Dive C, Hitekman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991; 64: 192–6.
   PubMed Web of Science ®Google Scholar
• Katan et al. 1991 (personal communication).
   Google Scholar
• Kerr if, Winterford CM, Harmon BV. Apoptosis: Its significance in cancer and cancer therapy [published erratum appears in Cancer 1994; 73: 3108]. Cancer 1994; 73: 2013–26.
   Google Scholar
• Lowe SW, Bodis S, McClatchey A, et al. p53 status and effects of cancer therapy in vivo. Science 1994; 266: 8807–10.
   Web of Science ®Google Scholar
• Waldman T, Lengauer C, Kinzler KW, et al. Uncoupling of S phase and mitosis induced by anti-cancer agents in cells lacking p21. Nature 1996; 381: 713–6.
   PubMed Web of Science ®Google Scholar
• Fan S, Smith ML, River III DJ, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifyllin. Cancer Res 1995; 55: 1649–54.
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Demers W, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56: 892–8.
   Google Scholar
• Wahl AF, Donaldson K, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72–9.
   PubMed Web of Science ®Google Scholar
• Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 459–64.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Dalbagni D, Sarkis A, Reuter VE. Genetic alterations associated with bladder cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia, PA: J. B. Lippin-cott Company, 1994: 71–83.
   Google Scholar
• Koss L Atlas of tumor pathology: Tumors of the urinary bladder (Fasicle 11), 2nd edn. Washington DC: Armed Forces Institute of Pathology, 1975.
   Google Scholar
• Fradet Y, Cordon-Cardo C. Tumor markers in the management of bladder cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P, eds. Principles and practice of genitourinary oncology. Philadelphia, PA: J. B. Lippincott Company, 1996: 231–8.
   Google Scholar
• Bonner RB, Hemstreet III GP, Fradet Y, Rao JY, Min KW, Hurst RE. Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer 1993; 72: 2461–9.
   PubMed Web of Science ®Google Scholar
• Hemstreet III GP, Hurst RE, Bonner RB, Jones PL, MM KW, Fradet Y. Alterations in phenotypic bio-chemical markers in bladder epithelium during tumo-rigenesis. Proc Natl Acad Sci USA 1993; 90: 8287–91.
   PubMed Web of Science ®Google Scholar
• Yamada T, Fukui I, Kobayashi T. The relationship of ABH(0) blood group antigen expression in intraepi-thelial dysplastic lesions to clinicopathologic proper-ties of associated transitional cell carcinoma of the bladder. Cancer 1991; 67: 1661–6.
   Google Scholar
• Orlow I, Lacombe L, Pellicer I, Delgado R, Szijan I, Cordon-Cardo C. Genotype and phenotype character-ization of the histoblood group ABO(H) in primary bladder tumors. Int J Cancer 1998; 75: 819–24.
   Google Scholar
• Hamden P. Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996; 78: 870–5.
   Google Scholar
• Bochner BH, Cote RJ, Weidner N, et al. Tumor angiogenesis is an independent prognostic factor in invasive transitional cell carcinoma of the bladder. J Natl Cancer Inst 1995; 87: 1603–12.
   PubMed Web of Science ®Google Scholar
• Grossfeld GD, Ginsberg DA, Stein JP, et al. Throm-bospondin-1 expression in transitional cell carcinoma of the bladder: association with p53 alterations, tumor angiogenesis and tumor progression. J Natl Cancer Inst 1997; 89: 219–27.
   PubMed Web of Science ®Google Scholar
• McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 2000: in press.
   Google Scholar
• Linehan WM, Cordon-Cardo C, Isaacs W. Molecular biology of genitourinary cancers. In: DeVita VT, Hellman S, Rosenberg SA, eds. Principles and practice of oncology, 5th edn. Philadelphia, PA: J. B. Lippincott Company, 1997: 1253–71.
   Google Scholar
• Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol 1998; 160: 645–59.
   PubMed Web of Science ®Google Scholar